Could a natural compound in food help aging hearts?
NCT ID NCT06186102
First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 5 times
Summary
This study tests whether spermidine, a natural substance found in foods like soy and aged cheese, can improve heart and muscle health in elderly people with coronary artery disease. 180 participants aged 65 and older will receive either spermidine capsules or a placebo for a period. Researchers will measure changes in heart mass, muscle mass, inflammation, and exercise capacity.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Spermidine (a dietary supplement)
- What this could lead to
- If it works, this could point toward a simple supplement to help elderly heart patients maintain heart and muscle function.
- What could go wrong
- This is a small, early-phase trial (180 people) testing a supplement, not a drug. Results may not lead to a proven treatment, and benefits may be modest or absent.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
187 people
The number who actually took part.
- Started
-
Jan 2024
- Finished
-
Jun 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
65 to 90 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 65 years * Chronic ischemic heart disease (previous revascularization or myocardial infarction) * Left ventricular ejection fraction of \> 40% And at least two of the following risk factors: * Type 2 diabetes, * Obesity (BMI ≥ 30 kg/m2), * Hypertension, * Previous LVEF \< 40%, * Left atrial volume index ≥ 30 mL/m2 * Left ventricular wall thickness ≥ 1.1 cm. Exclusion Criteria: * Unstable coronary syndrome * Significant and severe cardiac valve disease * Severe peripheral artery disease * Permanent atrial fibrillation * Pacemaker treatment * Chronic kidney disease with eGFR \<45 ml/min/1,73m2 * Severe comorbidity as judged by the investigator (such as severe pulmonary, neurological, or musculoskeletal disease) * Inability to give informed consent. Exclusion criteria for MRI: * Some metallic implants * Claustrophobia Exclusion criteria for muscle biopsy: * Treatment with either two antiplatelet drugs (aspirin and ADP-receptor antagonists) * Anticoagulants (warfarin, NOACs)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Aarhus University Hospital
Aarhus, Jutland, 8200, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Inflatable leg cuffs tested as a Two-for-One therapy for high blood pressure and erectile dysfunction
- Could monthly texts and automatic risk scores stop heart attacks before they start?
- Can heart rehab and brain training sharpen thinking?
- Can group singing and rhythm help Long-Term care residents with cognitive impairment?
- Can nurses and home monitors tame high blood pressure?
- Which exercise dose best helps kids with metabolic syndrome?